In this Management's Discussion and Analysis of Financial Condition and Results
of Operations ("MD&A"), Adtalem Global Education Inc., together with its
subsidiaries, is collectively referred to as "Adtalem," "we," "our," "us," or
similar references.

Discussions within this MD&A may contain forward-looking statements. See the
"Forward-Looking Statements" section preceding Part I of this Annual Report on
Form 10-K for details about the uncertainties that could cause our actual
results to be materially different than those expressed in our forward-looking
statements.

Throughout this MD&A, we sometimes use information derived from the Consolidated
Financial Statements in Item 8. "Financial Statements and Supplementary Data"
and the notes thereto but not presented in accordance with U.S. generally

                                       49

Table of Contents



accepted accounting principles ("GAAP"). Certain of these items are considered
"non-GAAP financial measures" under the Securities and Exchange Commission
("SEC") rules. See the "Non-GAAP Financial Measures and Reconciliations" section
for the reasons we use these non-GAAP financial measures and the reconciliations
to their most directly comparable GAAP financial measures.

Certain items presented in tables may not sum due to rounding. Percentages
presented are calculated from the underlying numbers in thousands. Discussions
throughout this MD&A are based on continuing operations unless otherwise noted.
The MD&A should be read in conjunction with the Consolidated Financial
Statements in Item 8. "Financial Statements and Supplementary Data" and the
notes thereto.

The following discussion is on the comparison between fiscal year 2020 and
fiscal year 2021 results. For a discussion on the comparison between fiscal year
2019 and fiscal year 2020 results, see the MD&A included in Adtalem's Annual
Report on Form 10-K for the fiscal year ended June 30, 2020, as filed with

the
SEC.

Segments

As of September 30, 2019, Adtalem eliminated its Business and Law reportable
segment when Adtalem Education of Brazil ("Adtalem Brazil") was classified as
discontinued operations and assets held for sale. In addition to the sale of
Adtalem Brazil, which was completed on April 24, 2020, during the second quarter
of fiscal year 2019, Adtalem divested Carrington College ("Carrington") and
DeVry University. In accordance with GAAP, we have classified the Adtalem
Brazil, Carrington, and DeVry University entities as "Assets Held for Sale" and
"Discontinued Operations" in all periods presented as applicable. As a result,
all financial results, disclosures, and discussions of continuing operations in
this Annual Report on Form 10-K exclude Adtalem Brazil, Carrington, and DeVry
University operations, unless otherwise noted. See Note 4 "Discontinued
Operations and Assets Held for Sale" to the Consolidated Financial Statements in
Item 8. "Financial Statements and Supplementary Data" for additional
discontinued operations information.

We present two reportable segments as follows:



Medical and Healthcare - Offers degree and non-degree programs in the medical
and healthcare postsecondary education industry. This segment includes the
operations of Chamberlain University ("Chamberlain"), American University of the
Caribbean School of Medicine ("AUC"), Ross University School of Medicine
("RUSM"), and Ross University School of Veterinary Medicine ("RUSVM"). AUC,
RUSM, and RUSVM are collectively referred to as the "medical and veterinary
schools."

Financial Services - Offers test preparation, certifications, conferences,
seminars, memberships, and subscriptions to business professionals in the areas
of accounting, anti-money laundering, banking, and mortgage lending. This
segment includes the operations of the Association of Certified Anti-Money
Laundering Specialists ("ACAMS"), Becker Professional Education ("Becker"),
OnCourse Learning ("OCL"), and EduPristine. On August 4, 2021, Adtalem announced
we are exploring strategic alternatives for the Financial Services segment.

"Home Office and Other" includes activities not allocated to a reportable segment. Financial and descriptive information about Adtalem's reportable segments is presented in Note 21 "Segment Information" to the Consolidated Financial Statements in Item 8. "Financial Statements and Supplementary Data."

Walden University Acquisition


On August 12, 2021, Adtalem completed the acquisition of all the issued and
outstanding equity interest in Walden e-Learning, LLC, a Delaware limited
liability company ("e-Learning"), and its subsidiary, Walden University, LLC, a
Florida limited liability company (together with e-Learning, "Walden"), from
Laureate Education, Inc. ("Laureate" or "Seller") in exchange for a purchase
price of $1.48 billion in cash, subject to certain adjustments set forth in the
Membership Interest Purchase Agreement (the "Agreement) (the "Acquisition"). See
the "Liquidity and Capital Resources" section of this MD&A for a discussion on
the financing used to fund the Acquisition. The risks and uncertainties related
to the Acquisition are described in Item 1A. "Risk Factors." Refer to the Form
8-K filed with the SEC on August 12, 2021 and Note 22 "Subsequent Event" to the
Consolidated Financial Statements in Item 8. "Financial Statements and
Supplementary Data" for additional information on the Acquisition.

                                       50

  Table of Contents

Fiscal Year 2021 Highlights

Financial and operational highlights for fiscal year 2021 include:

Adtalem revenue grew $60.4 million, or 5.7%, in fiscal year 2021 compared to

? the prior year. Both the Medical and Healthcare and Financial Services segments

saw increased revenue.

Net income attributable to Adtalem was $76.9 million ($1.49 diluted earnings

per share) in fiscal year 2021 compared to net loss attributable to Adtalem of

$85.3 million ($1.58 diluted loss per share) in the prior year. This increase

of $162.2 million was primarily driven by a pre-tax loss on the sale of Adtalem

Brazil of $287.6 million recorded in fiscal year 2020 and a pre-tax legal

settlement loss of $45.0 million recorded in fiscal year 2020 (see Note 20.

"Commitments and Contingencies" to the Consolidated Financial Statements in

Item 8. "Financial Statements and Supplementary Data"), partially offset by a

pre-tax gain of $110.7 million recorded in fiscal year 2020 on the

deal-contingent foreign currency hedge arrangement entered into in connection

? with the sale of Adtalem Brazil completed on April 24, 2020 to economically

hedge the Brazilian Real denominated purchase price through mitigation of the

currency exchange rate risk, and $31.6 million in business acquisition and

integration expense and $26.7 million in pre-acquisition interest expense

recorded in fiscal year 2021. Net income from continuing operations

attributable to Adtalem excluding special items of $153.7 million ($2.98

diluted earnings per share) increased $30.1 million ($0.70 per share), or

24.4%, in fiscal year 2021 compared to the prior year. This increase was driven

by revenue growth at Chamberlain, AUC, RUSVM, and OCL, which resulted in

improved operating income for these businesses. The increase was partially

offset by a revenue decrease at RUSM and increased costs for sales, marketing,

and employee benefits, which resulted in lower operating income.

For the May 2021 session, new and total student enrollment at Chamberlain

? increased 3.6% and 4.6%, respectively, compared to the same session last year.

Chamberlain continues to invest in its programs, student services, and campus

locations.

? For the May 2021 semester, new enrollment at the medical and veterinary schools

increased 12.3% compared to the same semester last year.

? ACAMS memberships have increased to more than 83,000 as of June 30, 2021

compared to more than 81,000 as of June 30, 2020.

OCL experienced strong revenue growth in its mortgage loan officer training and

? continuing education business, attributable to increased demand in the current

strong mortgage market.

Adtalem repurchased a total of 2,929,906 shares of Adtalem's common stock under

its share repurchase programs at an average cost of $34.13 per share during

fiscal year 2021. Repurchases were suspended on March 12, 2020 due to the

economic uncertainty caused by COVID-19 pandemic. In November 2020, Adtalem

? resumed repurchases under its share repurchase programs. Repurchases were again

suspended in May 2021 after achieving management's target of $100 million in

repurchases for fiscal year 2021. The timing and amount of any future

repurchases will be determined based on an evaluation of market conditions and

other factors.

Overview of the Impact of COVID-19


On March 11, 2020, the novel coronavirus ("COVID-19") outbreak was declared a
pandemic by the World Health Organization. COVID-19 has had tragic consequences
across the globe and altered business and consumer activity across many
industries. Management initiated several changes to the operations of our
institutions and administrative functions in order to protect the health of
Adtalem employees, students, and customers and to mitigate the financial effects
of COVID-19 and its resultant economic slowdown. We will continue to evaluate,
and if appropriate, adopt other measures in the future required for the ongoing
safety of our students, customers, and employees.

                                       51

  Table of Contents

Results of Operations

In fiscal year 2021, COVID-19 resulted in estimated revenue losses of
approximately $47 million, operating income losses of approximately $33 million,
and loss of earnings per share of approximately $0.50. In fiscal year 2020,
COVID-19 resulted in estimated revenue losses of approximately $29 million,
operating income losses of approximately $19 million and loss of earnings per
share of approximately $0.28. Management anticipates further negative COVID-19
effects to consolidated revenue, operating income, net income, and earnings per
share in fiscal year 2022 and beyond or as long as social distancing and other
measures established to combat COVID-19 continue to disrupt the normal business
operations of our convention operations and Financial Services customers. We
also expect higher variable expenses associated with bringing students back to
campus and providing a safe environment in the context of COVID-19 as we
continue to move back to in-person instruction across both segments. COVID-19
effects on fiscal year 2021 and 2020 results of operations of the Adtalem
institutions are described below.

?Chamberlain: Approximately 30% of Chamberlain's students are based at campus
locations and pursuing their Bachelor of Science in Nursing ("BSN") degree; at
the onset of the COVID-19 outbreak, all campus-based students transitioned to
online learning for didactic and select clinical experiences. The remaining 70%
of Chamberlain's students are enrolled in online programs that may or may not
have clinical components and those programs continued to successfully operate.
For the September 2020 session, students and employees returned to several
Chamberlain campuses for limited onsite instruction. COVID-19 did not result in
significant revenue losses or increased costs at Chamberlain in fiscal year 2021
and 2020. The extent of the impact in fiscal year 2022 and beyond will be
determined based on the length and severity of the effects of COVID-19, the
efficacy and distribution of the vaccines, and whether any pandemic surge
affects healthcare facilities' ability to continue to provide clinical
experiences, most of which have resumed. Chamberlain has clinical partnerships
with healthcare facilities across the U.S., minimizing the risk of suspension of
all onsite clinical education experiences.

The Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") became
law on March 27, 2020. It provided funding for higher education, which included
emergency grants, known as Higher Education Emergency Relief Fund ("HEERF") I,
for students who experienced an unexpected expense or hardship as a result of
the disruption of campus operations due to COVID-19. In June 2020, Chamberlain
received a total of $8.0 million in HEERF I grant funding, for which
distribution to eligible students commenced on July 7, 2020. The Consolidated
Appropriations Act, 2021 (the "Appropriations Act") became law on December 27,
2020. The Appropriations Act includes the Coronavirus Response and Relief
Supplemental Appropriations Act, 2021 and is referred to as HEERF II. In
February 2021, Chamberlain was awarded $7.1 million in HEERF II grant funding,
all of which was disbursed to students in fiscal year 2021. The American Rescue
Plan Act of 2021 (the "Rescue Act") became law on March 11, 2021 and authorized
additional grant funds for students, known as HEERF III. Chamberlain was
allocated $4.6 million in HEERF III grant funds that are dedicated solely to
students who meet the institution's eligibility criteria and which were
disbursed to students in July 2021. HEERF I, II, and III funds have been a
one-time emergency student financial aid resource associated with the COVID-19
pandemic and recovery, and thus are not anticipated to be renewed in the future.
All of the funds received under HEERF I, II, and III were redistributed to
eligible students who demonstrated exceptional need. As a result, these funds
were recorded as zero net revenue in their respective periods and, thus, did not
have a significant effect on the results of operations, financial position, or
cash flows of Adtalem in fiscal year 2021 and 2020.

?AUC and RUSM: Medical students enrolled in the basic science portion of their
program transitioned to online learning at the onset of the COVID-19 outbreak.
Many students left St. Maarten and Barbados to continue their studies remotely
from other locations. AUC and RUSM were able to provide remote learning and have
students remain eligible for U.S. federal financial aid assistance under a
waiver provided by the U.S. Secretary of Education that was included in the
CARES Act signed into law in March 2020. The waiver was dependent upon the host
country's coronavirus state of emergency declaration. The nation of St. Maarten
lifted their declaration in June 2020, and as a result, AUC's ability to offer
distance education ended after the September 2020 semester, requiring all AUC
students to return to St. Maarten for basic science instruction effective
January 2021. A limited number of RUSM students began returning to Barbados in
January and May 2021 with a full return expected for the September 2021
semester. The Appropriations Act was signed into law in December 2020, and
corrected technical errors in the CARES Act, which clarified the authority to
operate via distance learning due to a declaration of an emergency in an
applicable country or a qualifying emergency in the U.S. This section also
extends these flexibilities through the end of the qualifying emergency or June
30, 2022, whichever is later. The Appropriations Act provides Adtalem's foreign
institutions the ability to continue distance education without

                                       52

Table of Contents


disruption to their students' Title IV federal financial aid. COVID-19 did not
result in significant revenue losses or increased costs within the basic science
programs at the medical schools in fiscal year 2021 and 2020, except with
respect to housing operations, as discussed below. COVID-19 will likely have
minimal impact on basic science program revenue in fiscal year 2022, except with
respect to housing operations, unless students choose to not continue or start
their studies during this time of uncertainty. The extent of the impact in
fiscal year 2022 and beyond will be determined based on the length and severity
of the effects of COVID-19 and the efficacy and distribution of the vaccines.
Students who have completed their basic science education progress to clinical
rotations in the U.S. and the U.K. Clinical rotations for all students were
temporarily suspended in March 2020; however, some students were able to
participate in online clinical elective courses during this transition period
and beyond. The COVID-19 surge experienced during the winter in fiscal year 2021
across the U.S. caused many partner hospitals to again reduce the hours
available for clinical experiences. As a result, although many students were
able to resume their clinical education during the second quarter of fiscal year
2021, management estimates that not being able to offer a full clinical program
reduced combined revenue of AUC and RUSM by approximately $21 million and $13
million and operating income by approximately $14 million and $10 million in
fiscal year 2021 and 2020, respectively. As of June 2021, all clinical partners
of AUC and RUSM have resumed their clinical programs; however, should future
surges in COVID-19 again restrict the number of clinical hours available to our
students, we could experience negative effects on revenue and operating income
in fiscal year 2022 and beyond. Adtalem has clinical partnerships with hospitals
across the U.S. and the U.K., minimizing the risk of suspension of all onsite
clinical education experiences. In addition to the loss of clinical revenue and
operating income at AUC and RUSM, management estimates that housing and student
transportation revenue of approximately $13 million and $4 million and operating
income losses of approximately $10 million and $2 million in fiscal year 2021
and 2020, respectively, were also lost due to students leaving the St. Maarten
and Barbados campuses to continue basic science studies remotely.
?RUSVM: All basic science veterinary students transitioned to online learning
beginning in March 2020. Many students left St. Kitts in March 2020 to continue
their studies remotely from other locations. As of May 2021, all basic science
students have returned to St. Kitts where lectures continue to be delivered
remotely and labs are in-person. COVID-19 did not result in significant revenue
losses or increased costs within the basic science program in fiscal year 2021
and 2020. We do not expect a significant impact from COVID-19 on the basic
science program in fiscal year 2022, unless students choose to not continue or
start their studies during this time of uncertainty. RUSVM continues to be able
to provide remote learning during the pandemic and have students remain eligible
for U.S. federal financial aid assistance under a waiver provided by the CARES
Act and the Appropriations Act through the end of the qualifying emergency or
June 30, 2022, whichever is later, as described above. Students who have
completed their basic science education progress to clinical rotations at select
universities in the U.S., Canada, Australia, Ireland, New Zealand, and the U.K.
A few universities initially suspended onsite clinical experiences and
transitioned students to online education. All universities have since resumed
onsite clinical courses. The initial suspensions did not significantly reduce
revenue or operating income in fiscal year 2021 and 2020. While we do not expect
a significant impact from COVID-19 at RUSVM, the extent of the impact on
clinical experiences in fiscal year 2022 and beyond will be determined based on
the length and severity of the effects of COVID-19 and the efficacy and
distribution of the vaccines.
?Financial Services: Most Financial Services content, including exam
preparation, certification training, continuing education, and subscriptions is
delivered online. Any classroom-based learning has been moved to online. No
significant COVID-19 related cost increases were realized in Financial Services
in fiscal year 2021 and 2020. COVID-19 did result in estimated revenue losses of
approximately $12 million and $12 million and operating income losses of
approximately $8 million and $5 million in fiscal year 2021 and 2020,
respectively, primarily driven by the cancellation of ACAMS live conferences.
Fiscal year 2020 lost revenue and operating income was also impacted at Becker
from Prometric, a global leader in the provision of technology-enabled testing
and assessment solutions, closing CPA testing sites, along with a number of CPA
firms either delaying start dates for, or rescinding altogether, offers of
employment to recent college graduates. This dampened a key driver of demand in
the fourth quarter of fiscal year 2020, which is normally a time of robust
demand because of the influx of new college graduates looking to begin their CPA
exam preparation. ACAMS live conference revenue is not expected to return to
pre-pandemic levels until COVID-19 restrictions are fully lifted and customer
apprehension dissipates. COVID-19 is expected to negatively impact Financial
Services revenue and operating income in fiscal year 2022 and beyond driven by
lower ACAMS live conference revenue and possible weakness in demand at Becker,
primarily with CPA firm customers. Virtual conferences were conducted in late
fiscal year 2020 and throughout fiscal year 2021, and additional conference
revenue could be replaced with virtual or hybrid events in the future; however,
virtual conferences are unlikely to generate the same level of revenue and
operating income as live conferences. Loss of

                                       53

Table of Contents


conference revenue is likely in fiscal year 2022 as ACAMS has only recently been
able to offer a limited number of live conferences, mostly overseas. Large live
and hybrid conferences in the U.S. are not expected to resume until possibly
September 2021, and management expects any such events will not initially
generate pre-pandemic levels of revenue. Management believes that other than the
ACAMS conferences, longer-term operating results in the Financial Services
segment will not be significantly affected by COVID-19 unless there are major
employment losses with accounting professionals and recent accounting graduates,
or in the banking and mortgage sectors. This is not known and cannot be
predicted at this time. At Becker, CPA testing sites are operating with
available capacity; however, management believes hiring at CPA firms has not yet
fully recovered.
?Administrative Operations: Most institution and home office administrative
operations continue to principally be performed remotely. This includes
operations in both the U.S. and all foreign locations. These remote work
arrangements have not adversely affected Adtalem's ability to maintain
operations, financial reporting systems, internal control over financial
reporting, or disclosure controls and procedures. The effectiveness of our
remote technology enables our ability to maintain these systems and controls.
Management does not anticipate Adtalem will be materially impacted by any
constraints or other impacts on our human capital resources and productivity.
Travel restrictions and border closures are not expected to have a material
impact on our ability to operate and achieve operational goals. While recent
travel expenditures have decreased, we would expect these costs to increase as
the effects of COVID-19 dissipate. No significant home office costs were
incurred related to COVID-19 in fiscal year 2021 and 2020, and no such costs are
anticipated in fiscal year 2022 and beyond.

Although COVID-19 has had a negative effect on the operating results of all four
reporting units that contain goodwill and indefinite-lived intangible assets as
of June 30, 2021, at this time none of the effects are considered significant
enough to create an impairment triggering event since our annual goodwill
impairment assessment on May 31, 2021. While management has considered the
effects of the COVID-19 pandemic in evaluating the existence of an impairment
triggering event, it is possible that effects to revenue and cash flows will be
more significant than currently expected if the effects of the COVID-19 pandemic
and social distancing measures established to combat the virus continue for an
extended period of time. Should economic conditions deteriorate beyond
expectations in fiscal year 2022, an impairment triggering event could arise and
require reassessment of the fair values of goodwill and intangible assets.

Liquidity


Adtalem's cash and cash equivalents balance as of June 30, 2021, was $494.6
million. Adtalem generated $223.2 million in operating cash flow from continuing
operations in fiscal year 2021. In the event of unexpected market conditions or
negative economic changes, including those caused by COVID-19, that could
negatively affect Adtalem's earnings and/or operating cash flow, Adtalem
maintained a $300 million revolving credit facility with availability of $231.6
million as of June 30, 2021. As of August 12, 2021, Adtalem now maintains a $400
million revolving credit facility (as discussed in Note 13 "Debt" to the
Consolidated Financial Statements in Item 8. "Financial Statements and
Supplementary Data." Management currently projects that COVID-19 will continue
to have an effect on operations; however, we believe the current balances of
cash, cash generated from operations, and our New Credit Facility (as defined
and discussed in Note 13 "Debt" to the Consolidated Financial Statements in Item
8. "Financial Statements and Supplementary Data") will be sufficient to fund
both Adtalem's current domestic and international operations and growth plans in
the foreseeable future. See further discussion on the new financing executed to
close the Acquisition in the section of this MD&A titled "Liquidity and Capital
Resources."

                                       54

  Table of Contents

Results of Operations

The following table presents selected Consolidated Statements of Income (Loss) data as a percentage of revenue:




                                                         Year Ended June 30,
                                                     2021        2020        2019
Revenue                                               100.0 %     100.0 %     100.0 %
Cost of educational services                           44.0 %      46.6 %      46.5 %

Student services and administrative expense            37.8 %      37.6 %      35.4 %
Restructuring expense                                   0.9 %       2.7 %       5.2 %
Business acquisition and integration expense            2.8 %       0.0 %  

    0.0 %
Gain on sale of assets                                  0.0 %     (0.5) %       0.0 %
Settlement gains                                        0.0 %       0.0 %     (2.6) %

Total operating cost and expense                       85.5 %      86.5 %  

   84.6 %
Operating income                                       14.5 %      13.5 %      15.4 %
Net other (expense) income                            (3.1) %       9.0 %     (1.6) %
Income from continuing operations before income
taxes                                                  11.4 %      22.5 %      13.8 %
(Provision for) benefit from income taxes             (2.3) %       0.6 %     (3.2) %
Income from continuing operations                       9.1 %      23.1 %      10.5 %
Loss from discontinued operations, net of tax         (2.3) %    (31.3) %     (1.1) %
Net income (loss)                                       6.9 %     (8.2) %       9.4 %
Net loss (income) attributable to redeemable
noncontrolling interest                                 0.0 %       0.0 %     (0.0) %
Net income (loss) attributable to Adtalem               6.9 %     (8.1) %  

    9.4 %


Revenue

The following table presents revenue by segment detailing the changes from the
prior year (in thousands):


                                        Year Ended June 30, 2021
                                Medical and    Financial
                                Healthcare      Services     Consolidated
Fiscal year 2020 as reported   $     866,428   $  185,573   $    1,052,001
Organic growth                        40,473       19,906           60,379
Fiscal year 2021 as reported   $     906,901   $  205,479   $    1,112,380

Fiscal year 2021 % change:
Organic growth                           4.7 %       10.7 %            5.7 %


Medical and Healthcare

Revenue in the Medical and Healthcare segment increased 4.7%, or $40.5 million,
to $906.9 million in fiscal year 2021 compared to the prior year. The increase
in revenue in fiscal year 2021 is driven primarily by student enrollment
increases at Chamberlain. This increase was partially offset by an estimated
loss of approximately $13 million in housing and student transportation revenue
in fiscal year 2021 (compared to $4 million in fiscal year 2020), primarily at
RUSM as basic science students were not on campus for the full year due to
COVID-19 remote learning. COVID-19 related clinical revenue losses at AUC and
RUSM were approximately $21 million in fiscal year 2021 (compared to $13 million
in fiscal year 2020) driven by limitations at partner hospitals, which although
not as severe as earlier in the pandemic, were reinstituted when COVID-19 cases
surged across the U.S. during the winter in fiscal year 2021.

                                       55

  Table of Contents

Chamberlain

Chamberlain Student Enrollment:




                                                             Fiscal Year 2021
Session                            July 2020   Sept. 2020   Nov. 2020   Jan. 2021   Mar. 2021   May 2021
New students                           2,768        6,333       2,931       5,202       3,283      4,363

% change from prior year                15.5 %       13.2 %       8.1 %     (1.7) %       6.8 %      3.6 %
Total students                        32,198       35,525      34,387      35,750      35,702     34,930
% change from prior year                12.2 %       11.9 %      10.2 %    

  5.6 %       5.8 %      4.6 %

                                                             Fiscal Year 2020
Session                            July 2019   Sept. 2019   Nov. 2019   Jan. 2020   Mar. 2020   May 2020
New students                           2,396        5,595       2,711       5,293       3,073      4,213

% change from prior year               (5.0) %        2.9 %       3.6 %      11.2 %      12.7 %      5.4 %
Total students                        28,691       31,736      31,215      33,850      33,748     33,407
% change from prior year                 2.3 %        1.4 %       1.2 %    

4.6 % 5.1 % 8.2 %


Chamberlain revenue increased 10.2%, or $52.2 million, to $563.8 million in
fiscal year 2021 compared to the prior year, driven by increases in total
student enrollment during each of the fiscal year 2021 enrollment sessions
compared to the same session from the prior year as well as select tuition and
fee price increases. Management believes that the launch of new programs, the
addition of weekend and evening classes, the scaling provided by our
multi-campus model, and the effectiveness of recent marketing investments have
contributed to the enrollment increases. Chamberlain admitted its largest class
of campus students in September 2020.

Chamberlain currently operates 23 campuses in 15 states, including Chamberlain's newest campus in Irwindale, California, which began instruction in May 2021.

Tuition Rates:



Tuition for the Bachelor of Science in Nursing ("BSN") onsite degree program
ranges from $675 to $730 per credit hour. Tuition for the Registered Nurse to
BSN ("RN-to-BSN") online degree program is $590 per credit hour. Tuition for the
online Master of Science in Nursing ("MSN") degree program is $650 per credit
hour. Tuition for the online Family Nurse Practitioner ("FNP") degree program is
$665 per credit hour. Tuition for the online Doctor of Nursing Practice ("DNP")
degree program is $775 per credit hour. Tuition for the online Master of Public
Health ("MPH") degree program is $550 per credit hour. Tuition for the online
Master of Social Work ("MSW") degree program is $695 per credit hour. These
tuition rates do not include the cost of books, supplies, transportation, or
living expenses.

                                       56

  Table of Contents

Medical and Veterinary Schools

Medical and Veterinary Schools Student Enrollment:




                                   Fiscal Year 2021
Semester                   Sept. 2020   Jan. 2021   May 2021
New students                      920         589        611
% change from prior year          5.5 %      21.2 %     12.3 %
Total students                  5,850       5,292      5,126
% change from prior year          4.3 %     (6.2) %    (1.2) %

                                   Fiscal Year 2020
Semester                   Sept. 2019   Jan. 2020   May 2020
New students                      872         486        544
% change from prior year        (1.9) %       3.2 %      9.7 %
Total students                  5,608       5,643      5,186
% change from prior year        (4.7) %       1.7 %    (0.7) %


The medical and veterinary schools' revenue decreased 3.3%, or $11.7 million, to
$343.1 million in fiscal year 2021 compared to the prior year. The principal
drivers of the decrease were an estimated loss of approximately $13 million in
fiscal year 2021 in housing and student transportation revenue (compared to $4
million in fiscal year 2020), primarily at RUSM as basic science students were
not on campus for the full year due to COVID-19 remote learning. COVID-19
related clinical revenue losses at AUC and RUSM were approximately $21 million
in fiscal year 2021 (compared to $13 million in fiscal year 2020) driven by
limitations at partner hospitals, which although not as severe as earlier in the
pandemic, were reinstituted when COVID-19 cases surged across the U.S. during
the winter in fiscal year 2021. These decreases were partially offset with
student enrollment increases in the basic science programs at AUC and RUSVM.

In the May 2021 semester, total student enrollment increased at AUC and RUSVM
but declined at RUSM while new student enrollment increased at AUC and RUSM but
declined slightly at RUSVM. In the January 2021 semester, total student
enrollment increased at AUC and RUSVM but declined at RUSM while new student
enrollment increased at RUSM and RUSVM but declined slightly at AUC. The
declines in total student enrollment at RUSM for the January 2021 and May 2021
semesters were partially driven by the inability to offer clinical experiences
to all eligible students caused by the COVID-19 restrictions at partner
hospitals and partially driven by an increase in students waiting to pass their
USMLE Step 1 exam. In previous semesters during the COVID-19 pandemic, students
were able to supplement their clinical experience with elective online courses;
however, these electives are limited and most were completed. If a student has
not yet started in a clinical program, is not eligible to be enrolled in a
clinical program, or not participating in other educational experiences, they
are not included in the enrollment count for that semester. In the September
2020 semester, total student enrollment increased at AUC, RUSM, and RUSVM while
new student enrollment increased at AUC and RUSM but slightly declined at RUSVM
due to the large cohort of May 2020 Vet Prep students progressing to September
2020, which was at maximum enrollment capacity. Management is executing its plan
to differentiate the medical and veterinary schools from the competition, with a
core goal of increasing international students, increasing affiliations with
historically black colleges and universities ("HBCU") and Hispanic-serving
institutions ("HSI"), expanding AUC's medical education program based in the
U.K. in partnership with the University of Central Lancashire ("UCLAN"), and
improving the effectiveness of marketing and enrollment investments.

In September 2019, AUC opened its medical education program in the U.K. in
partnership with UCLAN. The program offers students a Post Graduate Diploma in
International Medical Sciences from UCLAN, followed by their Doctor of Medicine
degree from AUC. Students are eligible to do clinical rotations at AUC's
clinical sites, which include hospitals in the U.S., the U.K., and Canada. This
program is aimed at preparing students for the U.S. Medical Licensing
Examination ("USMLE").

                                       57

  Table of Contents

Tuition Rates:

Effective for semesters beginning in September 2020, tuition rates for the

? beginning basic sciences and final clinical rotation portions of AUC's medical

program are $23,240 and $26,000, respectively, per semester. These tuition

rates are unchanged from the prior academic year.

Effective for semesters beginning in September 2020, tuition rates for the

? beginning basic sciences and final clinical rotation portions of RUSM's medical

program are $24,170 and $26,676, respectively, per semester. These tuition

rates are unchanged from the prior academic year.

For students who entered the RUSVM program in September 2018 or later, the

tuition rate for the pre-clinical (Semesters 1-7) and clinical curriculum

(Semesters 8-10) is $20,873 per semester effective September 2020. For students

? who entered RUSVM before September 2018, tuition rates for the pre-clinical and

clinical curriculum are $19,387 and $24,339, respectively, per semester

effective September 2020. These tuition rates are unchanged from the prior

academic year.

The respective tuition rates for AUC, RUSM, and RUSVM do not include the cost of transportation, living expenses, or health insurance.

Financial Services



Revenue in the Financial Services segment increased 10.7%, or $19.9 million, to
$205.5 million in fiscal year 2021 compared to the prior year. The principal
driver of this increase was increased revenue at OCL, ACAMS, and Becker. At OCL,
the revenue increase was driven by the mortgage loan officer training and
continuing education business, attributable to increased demand in the current
strong mortgage market. At ACAMS, lost conference revenue was offset by
increases in certification and risk assessment revenue. ACAMS lost conference
revenue of approximately $12 million in fiscal year 2021 (compared to $7 million
in fiscal year 2020) from live conferences moving to a virtual format in
response to COVID-19 restrictions. ACAMS memberships have increased to more than
83,000 as of June 30, 2021 compared to more than 81,000 as of June 30, 2020,
driven by strong growth in the European region. At Becker, the revenue increase
was driven by growth in its continuing education product line and entry into the
Certified Management Accountant exam preparation market.

Cost of Educational Services



The largest component of cost of educational services is the cost of faculty and
staff who support educational operations. This expense category also includes
the costs of facilities, adjunct faculty, supplies, housing, bookstore, other
educational materials, student education-related support activities, and the
provision for bad debts. The following table presents cost of educational
services by segment detailing the changes from the prior year (in thousands):


                                                Year Ended June 30, 2021
                                Medical and    Financial     Home Office
                                Healthcare      Services      and Other      Consolidated

Fiscal year 2020 as reported $ 455,123 $ 32,889 $ 2,042 $ 490,054 Cost increase (decrease)

                 662      (1,561)              78   

(821)


Fiscal year 2021 as reported   $     455,785   $   31,328   $       2,120   $      489,233

Fiscal year 2021 % change:
Cost increase (decrease)                 0.1 %      (4.7) %            NM            (0.2) %


Cost of educational services decreased 0.2%, or $0.8 million, to $489.2 million
in fiscal year 2021 compared to the prior year. Cost decreased in fiscal year
2021 primarily driven by decreased bad debt expense of $4.6 million primarily
related to the credit extension programs at the medical and veterinary schools,
cost control initiatives across all institutions, and lower costs of
approximately $14 million in fiscal year 2021 (compared to $10 million in fiscal
year 2020) associated with campus closure, reduced clinical rotations, lower
services, including housing services, and ACAMS live conferences, due to the
COVID-19 related revenue losses as noted above. These decreases were partially
offset by increased costs at Chamberlain and the basic science programs at the
medical and veterinary schools to support growth.

                                       58

Table of Contents



As a percentage of revenue, cost of educational services was 44.0% in fiscal
year 2021 compared to 46.6% in the prior year. The decrease in the percentage
was primarily the result cost control and leveraging our infrastructure in both
Medical and Healthcare and Financial Services, as well as decreased bad debt
expense related to the credit extension programs at the medical and veterinary
schools.

Student Services and Administrative Expense


The student services and administrative expense category includes expenses
related to sales, student admissions, marketing and advertising, general and
administrative, curriculum development, and amortization expense of finite-lived
intangible assets related to business acquisitions. The following table presents
student services and administrative expense by segment detailing the changes
from the prior year (in thousands):


                                                Year Ended June 30, 2021
                                Medical and    Financial     Home Office
                                Healthcare      Services      and Other      Consolidated
Fiscal year 2020 as reported   $     243,560   $  130,221   $      22,057   $      395,838
Cost increase                         10,854       12,524           1,051           24,429
Fiscal year 2021 as reported   $     254,414   $  142,745   $      23,108   $      420,267

Fiscal year 2021 % change:
Cost increase                            4.5 %        9.6 %            NM              6.2 %


Student services and administrative expense increased 6.2%, or $24.4 million, to
$420.3 million in fiscal year 2021 compared to the prior year. Expense increased
primarily due to increased sales and marketing expense of $17.9 million in
fiscal year 2021 to support continued growth, and an increase in employee
benefit costs of $7.9 million. These increased costs were partially offset with
cost control initiatives across all institutions.

As a percentage of revenue, student services and administrative expense was 37.8% in fiscal year 2021 compared to 37.6% in the prior year.

Restructuring Expense



Restructuring expense in fiscal year 2021 was $9.8 million compared to $28.6
million in fiscal year 2020. The primary driver of the decreased restructure
expense in fiscal year 2021 was the result of the higher amount of charges in
fiscal year 2020 related to real estate consolidations at Adtalem's home office
and the sale of Becker's courses for healthcare students. See Note 6
"Restructuring Charges" to the Consolidated Financial Statements in Item 8.
"Financial Statements and Supplementary Data" for additional information on
restructuring charges.

We have completed our current restructuring plans. However, we continue to incur
restructuring charges or reversals related to exiting leased space from previous
restructuring activities. Management may institute future restructuring plans.

Business Acquisition and Integration Expense


Business acquisition and integration expense in fiscal year 2021 was $31.6
million. These are transaction costs associated with entering into the Agreement
to acquire Walden and costs associated with integrating Walden into Adtalem. We
expect to incur additional integration costs in fiscal year 2022. There was no
corresponding expense in fiscal year 2020.

Gain on Sale of Assets



On September 27, 2019, Adtalem closed on the sale of its Columbus, Ohio, campus
facility. Net proceeds of $6.4 million from the sale of this facility resulted
in a gain on the sale of $4.8 million in fiscal year 2020. This gain was
recorded at Adtalem's home office, which is classified as "Home Office and
Other" in Note 21 "Segment Information" to the Consolidated Financial Statements
in Item 8. "Financial Statements and Supplementary Data." There was no
corresponding gain in fiscal year 2021.

                                       59

  Table of Contents

Operating Income

The following table presents operating income by segment detailing the changes from the prior year (in thousands):




                                                          Year Ended June 30, 2021
                                         Medical and     Financial     Home Office
                                         Healthcare      Services       and Other      Consolidated
Fiscal year 2020 as reported            $     166,037   $    17,622   $    (41,399)   $      142,260
Organic change                                 28,959         8,941         (1,129)           36,771
Restructuring expense change                    1,707         1,798          15,319           18,824
Business acquisition and integration
expense change                                      -             -        (31,593)         (31,593)
Gain on sale of assets change                       -             -         (4,779)          (4,779)
Fiscal year 2021 as reported            $     196,703   $    28,361   $   

(63,581) $ 161,483




The following table presents a reconciliation of operating income (GAAP) to
operating income excluding special items (non-GAAP) by segment (in thousands):


                                                          Year Ended June 30,
                                                                             Increase
                                                   2021          2020       (Decrease)
Medical and Healthcare:
Operating income (GAAP)                         $  196,703    $  166,037          18.5 %
Restructuring expense                                    -         1,707
Operating income excluding special items
(non-GAAP)                                      $  196,703    $  167,744          17.3 %

Financial Services:
Operating income (GAAP)                         $   28,361    $   17,622          60.9 %
Restructuring expense                                3,044         4,842
Operating income excluding special items
(non-GAAP)                                      $   31,405    $   22,464          39.8 %

Home Office and Other:
Operating loss (GAAP)                           $ (63,581)    $ (41,399)        (53.6) %
Restructuring expense                                6,760        22,079
Business acquisition and integration expense        31,593             -
Gain on sale of assets                                   -       (4,779)
Operating loss excluding special items
(non-GAAP)                                      $ (25,228)    $ (24,099)         (4.7) %

Adtalem Global Education:
Operating income (GAAP)                         $  161,483    $  142,260          13.5 %
Restructuring expense                                9,804        28,628
Business acquisition and integration expense        31,593             -
Gain on sale of assets                                   -       (4,779)
Operating income excluding special items
(non-GAAP)                                      $  202,880    $  166,109

22.1 %




Total consolidated operating income increased 13.5%, or $19.2 million, to $161.5
million in fiscal year 2021 compared to the prior year. Consolidated operating
income excluding special items increased 22.1%, or $36.8 million, to $202.9
million in fiscal year 2021 compared to the prior year. The primary drivers of
this increase were an increase in revenue of $60.4 million, primarily at
Chamberlain, which generated higher incremental operating income than the lost
revenue sources at other institutions due to COVID-19, decreased bad debt
expense of $4.6 million, primarily related to the credit extension programs at
the medical and veterinary schools, and efforts to manage salary, travel, and
discretionary spending across the organization. The positive influences on
operating income were partially offset by increased sales and marketing expense
of $17.9 million in fiscal year 2021 to support continued growth, and an
increase of $7.9 million in employee benefit costs. In addition, the effects of
COVID-19 reduced operating income in fiscal year 2021 by approximately $33
million (compared to $19 million in fiscal year 2020), primarily driven by the
loss of AUC and RUSM clinical revenue, RUSM housing and student transportation
revenue, and ACAMS conference revenue.

Medical and Healthcare

Medical and Healthcare segment operating income increased 18.5%, or $30.7 million, to $196.7 million in fiscal year 2021 compared to the prior year. The primary driver of the increase in operating income is the increased revenue at



                                       60

  Table of Contents

Chamberlain of $52.2 million in fiscal year 2021, which generated higher
incremental operating income than the lost revenue sources due to COVID-19, as
discussed below. In addition, other drivers include decreased bad debt expense
of $3.4 million in fiscal year 2021, primarily related to the credit extension
programs at the medical and veterinary schools, and efforts to manage salary,
travel, and discretionary spending at all institutions. The positive influences
on operating income in fiscal year 2021 were partially offset by increased
marketing expense of $7.6 million in fiscal year 2021 to support continued
growth and increased employee benefit costs of $4.2 million. Estimated COVID-19
related loss of clinical revenue at AUC and RUSM contributed to approximately
$14 million in lost operating income in fiscal year 2021 (compared to $10
million in fiscal year 2020). Lower COVID-19 related housing and student
transportation revenue, primarily at RUSM as described above, resulted in
approximately $10 million in lost operating income in the fiscal year 2021
(compared to $2 million in fiscal year 2020).

Financial Services



Financial Services segment operating income increased 60.9%, or $10.7 million,
to $28.4 million in fiscal year 2021 compared to the prior year. Segment
operating income excluding special items increased 39.8%, or $8.9 million, in
fiscal year 2021 compared to the prior year. The primary driver of this increase
was an increase in revenue at OCL, ACAMS, and Becker, which resulted in improved
operating income. This increase was partially offset by increased sales and
marketing expense of $10.3 million in fiscal year 2021. Conference revenue
decreases at ACAMS due to COVID-19, as described above, drove approximately $8
million in lost operating income in fiscal year 2021 (compared to $5 million in
fiscal year 2020); however, this decrease was fully offset by improved operating
income from other ACAMS operations.

Net Other (Expense) Income



Net other expense in fiscal year 2021 was $34.6 million compared to net other
income of $94.9 million in the prior year. The increase in net other expense was
primarily the result of a pre-tax gain of $110.7 million in fiscal year 2020 on
the deal-contingent foreign currency hedge arrangement entered into on October
18, 2019 in connection with the sale of Adtalem Brazil, which was completed on
April 24, 2020, to economically hedge the Brazilian Real denominated purchase
price through mitigation of the currency exchange rate risk (as discussed in
Note 4 "Discontinued Operations and Assets Held for Sale" to the Consolidated
Financial Statements in Item 8. "Financial Statements and Supplementary Data").
The derivative associated with the hedge did not qualify for hedge accounting
treatment under Accounting Standards Codification ("ASC") 815, and as a result,
all changes in fair value were recorded within the income statement. In
addition, interest expense increased in fiscal year 2021 driven by $26.7 million
in pre-acquisition interest expense, which partially offset our lower interest
expense on our current Credit Facility driven by the repayment of debt in the
fourth quarter of fiscal year 2020 using the proceeds from the sale of Adtalem
Brazil.

(Provision for) Benefit from Income Taxes


Our effective income tax rate ("ETR") from continuing operations can differ from
the 21% U.S. federal statutory rate due to several factors, including the rate
of tax applied by state and local jurisdictions, the rate of tax applied to
earnings outside the U.S., tax incentives, changes in valuation allowances,
liabilities for uncertain tax positions, and tax benefits on stock-based
compensation awards. Additionally, our ETR is impacted by the provisions from
the Tax Cuts and Jobs Act of 2017 (the "Tax Act"), which primarily includes a
tax on global intangible low-taxed income ("GILTI"), a deduction for foreign
derived intangible income ("FDII"), and a limitation of tax benefits on certain
executive compensation. The impact of the Tax Act may be revised in future
periods as we obtain additional data and consider any new regulations or
guidance that may be released.

The ETR from continuing operations in fiscal year 2021 was positive 19.9%, an
increase from negative 2.7% in fiscal year 2020. This increase is primarily due
to not recording a tax provision on the pre-tax gain of $110.7 million in fiscal
year 2020 on the deal-contingent foreign currency hedge arrangement entered into
in connection with the sale of Adtalem Brazil completed on April 24, 2020 (see
Note 4 "Discontinued Operations and Assets Held for Sale" to the Consolidated
Financial Statements in Item 8. "Financial Statements and Supplementary Data"
for additional information). Also, during fiscal year 2020, a net tax benefit
special item of $25.7 million was recorded related to a former subsidiary
investment loss claimed for the tax year ended June 30, 2018. Excluding the
one-time effects of the derivative contract and the tax benefit on a former
subsidiary investment loss in fiscal year 2020 (a non-GAAP financial measure),
the ETR from continuing

                                       61

  Table of Contents

operations in fiscal year 2021 and 2020 was 19.9% and 15.3%, respectively. This
increase in the fiscal year 2021 rate was driven by a decrease in the percentage
of earnings from foreign operations compared to the prior year.

On December 27, 2020, the Appropriations Act was enacted in response to the
COVID-19 pandemic. The Appropriations Act, among other things, temporarily
extends through December 31, 2025, certain expiring tax provisions, including
look-through treatment of payments of dividends, interest, rents, and royalties
received or accrued from related controlled foreign corporations. Additionally,
the Appropriations Act enacts new provisions and extends certain provisions
originated within the CARES Act, enacted on March 27, 2020, including an
extension of time for repayment of the deferred portion of employees' payroll
tax through December 31, 2021, and a temporary allowance for full deduction of
certain business meals. Adtalem has elected not to defer the employees' portion
of payroll tax. Management does not expect that the other provisions of the
Appropriations Act would result in a material tax or cash benefit.

On March 11, 2021, the Rescue Act was enacted in response to the COVID-19
pandemic. The Rescue Act, among other things, expands the number of employees
subject to the tax deductibility limitation of employee compensation in excess
of $1 million for tax years beginning after December 31, 2026 and repeals the
election for U.S. affiliated groups to allocate interest expense on a worldwide
basis. Management does not expect that the other provisions of the Rescue Act
would result in a material tax or cash detriment.

Discontinued Operations



Beginning in the second quarter of fiscal year 2018, DeVry University operations
were classified as discontinued operations. Beginning in the fourth quarter of
fiscal year 2018, Carrington operations were classified as discontinued
operations. Beginning in the first quarter of fiscal year 2020, Adtalem Brazil
operations were classified as discontinued operations. The divestitures of
Carrington and DeVry University operations were completed in the second quarter
of fiscal year 2019 and the divestiture of Adtalem Brazil operations was
completed in the fourth quarter of fiscal year 2020. We continue to incur costs,
principally attorney fees, associated with ongoing litigation and settlements
related to the DeVry University divestiture which is classified as expense
within discontinued operations.

Total loss from discontinued operations for the year ended June 30, 2021 was
$25.1 million, which was the result of costs from the ongoing litigation and
settlements related to the DeVry University divestiture.

Total loss from discontinued operations for the year ended June 30, 2020 was
$329.3 million. This loss consisted of the following: (i) a loss of $62.6
million driven by the operating results of Adtalem Brazil and ongoing litigation
costs, settlements, and other divestiture costs related to the DeVry University,
Carrington, and Adtalem Brazil divestitures; (ii) a loss on the sale of Adtalem
Brazil of $287.6 million, which included a $293.4 million loss recognized from
the reclassification of the cumulative foreign currency translation adjustments
from other comprehensive income; and (iii) a benefit from income taxes of $20.8
million associated with the items listed above.

Management no longer discloses other discussions of operating results of these entities as comparable results are no longer meaningful.

Regulatory Environment

Student Payments



Adtalem's primary source of liquidity is the cash received from payments for
student tuition, books, other educational materials, and fees. These payments
include funds originating as financial aid from various federal and state loan
and grant programs, student and family educational loans ("private loans"),
employer educational reimbursements, scholarships, and student and family
financial resources. Adtalem continues to provide financing options for its
students, including Adtalem's credit extension programs.

                                       62

Table of Contents



The following table, which excludes Adtalem Brazil, Carrington, and DeVry
University revenue, summarizes Adtalem's revenue by fund source as a percentage
of total revenue for fiscal years 2020 and 2019. Final data for fiscal year

2021
is not yet available.


                                                                     Fiscal Year
                                                                    2020      2019

Federal assistance (Title IV) program funding (grants and loans) 59 %

      59 %
Private loans                                                           2 %

2 % Student accounts, cash payments, private scholarships, employer and military provided tuition assistance, and other

                    39 %      39 %
Total                                                                 100 %     100 %


The pattern of cash receipts during the year is seasonal. Adtalem's cash
collections on accounts receivable peak at the start of each institution's term.
Accounts receivable reach their lowest level at the end of each institution's
term.

Financial Aid

Like other higher education companies, Adtalem is highly dependent upon the
timely receipt of federal financial aid funds. All financial aid and assistance
programs are subject to political and governmental budgetary considerations. In
the U.S., the Higher Education Act ("HEA") guides the federal government's
support of postsecondary education. If there are changes to financial aid
programs that restrict student eligibility or reduce funding levels, Adtalem's
financial condition and cash flows could be materially and adversely affected.
See Item 1A. "Risk Factors" for a discussion of student financial aid related
risks.

In addition, government-funded financial assistance programs are governed by
extensive and complex regulations in the U.S. Like any other educational
institution, Adtalem's administration of these programs is periodically reviewed
by various regulatory agencies and is subject to audit or investigation by other
governmental authorities. Any violation could be the basis for penalties or
other disciplinary action, including initiation of a suspension, limitation, or
termination proceeding.

If the U.S. Department of Education ("ED") determines that we have failed to
demonstrate either financial responsibility or administrative capability in any
pending program review, or otherwise determines that an institution has violated
the terms of its Program Participation Agreement ("PPA"), we could be subject to
sanctions including: fines, penalties, reimbursement for discharged loan
obligations, a requirement to post a letter of credit and/or suspension or
termination of our eligibility to participate in the Title IV programs.

During the fourth quarter of fiscal year 2020 and the first quarter of fiscal
year 2021, ED provisionally recertified AUC, RUSM, and RUSVM's Title IV PPAs
with expiration dates of December 31, 2022, March 31, 2023, and June 30, 2023,
respectively. The provisional nature of the agreements stemmed from increased
and/or repeated Title IV compliance audit findings. No financial ramifications,
such as a letter of credit, heightened cash monitoring, or student enrollment
limitations, were imposed on any of these institutions. While corrective actions
have been taken to resolve past compliance matters and eliminate the incidence
of repetition, if AUC, RUSM, or RUSVM fail to maintain administrative capability
as defined by ED while under provisional status or otherwise fail to comply with
ED requirements, the institution(s) could lose eligibility to participate in
Title IV programs or have that eligibility adversely conditioned, which could
have a material adverse effect on the businesses, financial condition, results
of operations, and cash flows.

On October 13, 2016, DeVry University and ED reached a negotiated agreement (the
"ED Settlement") to settle the claims asserted in a Notice of Intent to Limit
from the Multi-Regional and Foreign School Participation Division of the Federal
Student Aid office of the Department of Education ("ED FSA"). Under the terms of
the ED Settlement, among other things, without admitting wrongdoing, DeVry
University agreed to certain compliance requirements regarding its past and
future advertising, that DeVry University's participation in Title IV programs
is subject to provisional certification for five years and that DeVry University
is required to post a letter of credit equal to the greater of 10% of DeVry
University's annual Title IV disbursements or $68.4 million for a five-year
period. The posted letter of credit continues to be posted by Adtalem following
the closing of the sale of DeVry University and reduces Adtalem's borrowing

capacity

                                       63

  Table of Contents

dollar-for-dollar under its Credit Facility (as defined in Note 13 "Debt" to the Consolidated Financial Statements in Item 8. "Financial Statements and Supplementary Data").



An ED regulation known as the "90/10 Rule" affects only proprietary
postsecondary institutions, such as Chamberlain, AUC, RUSM, and RUSVM. Under
this regulation, an institution that derives more than 90% of its revenue on a
cash basis from Title IV student financial assistance programs in two
consecutive fiscal years loses eligibility to participate in these programs for
at least two fiscal years. The Rescue Act enacted on March 11, 2021 amended the
90/10 rule to require that a proprietary institution derive no more than 90% of
its revenue from federal education assistance funds, including but not limited
to previously excluded U.S. Department of Veterans Affairs and military tuition
assistance benefits. This change is subject to negotiated rulemaking, which will
not begin prior to October 1, 2021. The amended rule will first apply to
institutional fiscal years beginning on or after January 1, 2023. The following
table details the percentage of revenue on a cash basis from federal financial
assistance programs (excluding the U.S. Department of Veterans Affairs and
military tuition assistance benefits) for each of Adtalem's Title IV-eligible
institutions for fiscal years 2020 and 2019. Final data for fiscal year 2021 is
not yet available.


                                                           Fiscal Year
                                                          2020     2019
Chamberlain University                                       62 %    62 %

American University of the Caribbean School of Medicine 81 % 75 % Ross University School of Medicine

                           85 %    83 %
Ross University School of Veterinary Medicine                84 %    83 %


In September 2016, Adtalem committed to voluntarily limit to 85% the amount of
revenue that each of its Title IV-eligible institutions derive from federal
funding, including the U.S. Department of Veterans Affairs and military tuition
assistance benefits. As disclosed in the third-party review reports that have
been made publicly available, Adtalem's institutions have met this lower
threshold for each fiscal year since the commitment was made. Adtalem is
committed to implementing measures to promote responsible recruitment and
enrollment, successful student outcomes, and informed student choice. Management
believes students deserve greater transparency to make informed choices about
their education. This commitment builds upon a solid foundation and brings
Adtalem to a new self-imposed level of public accountability and transparency.

A financial responsibility test is required for continued participation by an
institution's students in U.S. federal financial assistance programs. For
Adtalem's participating institutions, this test is calculated at the
consolidated Adtalem level. The test is based upon a composite score of three
ratios: an equity ratio that measures the institution's capital resources; a
primary reserve ratio that measures an institution's ability to fund its
operations from current resources; and a net income ratio that measures an
institution's ability to operate profitably. A minimum score of 1.5 is necessary
to meet ED's financial standards. Institutions with scores of less than 1.5 but
greater than or equal to 1.0 are considered financially responsible, but require
additional oversight. These institutions are subject to heightened cash
monitoring and other participation requirements. An institution with a score of
less than 1.0 is considered not financially responsible. However, an institution
with a score of less than 1.0 may continue to participate in the Title IV
programs under provisional certification. In addition, this lower score
typically requires that the institution be subject to heightened cash monitoring
requirements and post a letter of credit (equal to a minimum of 10% of the Title
IV aid it received in the institution's most recent fiscal year).

For the past several years, Adtalem's composite score has exceeded the required
minimum of 1.5. Changes to the manner in which the composite score is calculated
that were effective on July 1, 2020 has negatively affected Adtalem's composite
score for fiscal year 2021 and will continue to negatively affect future Adtalem
scores. At this time, management does not believe these changes by themselves
will result in the score falling below 1.5. However, as a result of the
acquisition of Walden and the related transactions, Adtalem expects its
consolidated composite score to fall below 1.5 at its next financial
responsibility test. If Adtalem becomes unable to meet requisite financial
responsibility standards within the regulations, management believes it will be
able to otherwise demonstrate its ability to continue to provide educational
services; however, our institutions could still be subject to heightened cash
monitoring or be required to post a letter of credit to continue to participate
in federal and state financial assistance programs.

                                       64

Table of Contents

Liquidity and Capital Resources


Adtalem's consolidated cash and cash equivalents balance of $494.6 million and
$500.5 million as of June 30, 2021 and 2020, respectively, included cash and
cash equivalents held at Adtalem's international operations of $127.2 million
and $70.1 million as of June 30, 2021 and 2020, respectively, which is available
to Adtalem for general corporate purposes. Cash balances are currently being
maintained to partially fund the proposed Acquisition, as discussed in the
previous section "Walden University Acquisition" of this MD&A.

Under the terms of Adtalem institutions' participation in financial aid
programs, certain cash received from state governments and ED is maintained in
restricted bank accounts. Adtalem receives these funds either after the
financial aid authorization and disbursement process for the benefit of the
student is completed, or just prior to that authorization. Once the
authorization and disbursement process for a particular student is completed,
the funds may be transferred to unrestricted accounts and become available for
Adtalem to use in operations. This process generally occurs during the academic
term for which such funds have been authorized. Cash in the amount of
$0.4 million and $0.6 million was held in restricted bank accounts as of June
30, 2021 and 2020, respectively. In addition, $818.6 million is recorded within
restricted cash on the Consolidated Balance Sheet as of June 30, 2021, which
represents cash held in an escrow account designated to fund the Acquisition and
is not available to Adtalem for general corporate purposes (see Note 13 "Debt"
to the Consolidated Financial Statements in Item 8. "Financial Statements and
Supplementary Data" for additional information).

Cash Flow Summary

Operating Activities



The following table provides a summary of cash flows from operating activities
(in thousands):


                                                              Year Ended June 30,
                                                              2021           2020

Income from continuing operations                          $   101,602    $

243,537


Non-cash items                                                 129,034     

16,204


Changes in assets and liabilities                              (7,478)     

(110,176)


Net cash provided by operating activities-continuing
operations                                                 $   223,158    $

149,565




Net cash provided by operating activities from continuing operations in fiscal
year 2021 was $223.2 million compared to $149.6 million in the prior year. The
increase of $112.8 million in non-cash items between fiscal year 2021 and 2020
was principally driven by the gain of $110.7 million recorded in income from
continuing operations in the prior year for the deal-contingent foreign currency
hedge arrangement entered into in connection with the sale of Adtalem Brazil
completed on April 24, 2020 to economically hedge the Brazilian Real denominated
purchase price through mitigation of the currency exchange rate risk (as
discussed in Note 4 "Discontinued Operations and Assets Held for Sale" to the
Consolidated Financial Statements in Item 8. "Financial Statements and
Supplementary Data"). The increase of $73.6 million in cash generated from
continuing operating activities between fiscal year 2021 and 2020 was primarily
due to timing of prepaid expense, accounts payable, accrued expense
disbursements, and deferred revenue. This includes changes in prepaid income
taxes, accrued payroll taxes and benefits, accounts payable, accrued income
taxes, accrued interest, and clinical partner payments.

Investing Activities



Capital expenditures in fiscal year 2021 were $48.7 million compared to
$44.1 million in the prior year. The capital expenditures in fiscal year 2021
include spending for Chamberlain new campus development, maintenance, and
Adtalem's home office information technology investments. Capital spending for
fiscal year 2022 will support continued investment for new campus development at
Chamberlain, maintenance at the medical and veterinary schools, and Adtalem's
home office. Management anticipates fiscal year 2022 capital spending to be in
the $50 to $60 million range, which excludes any capital spending related to
Walden. The source of funds for this capital spending will be from operations or
the New Credit Facility (as defined and discussed in Note 13 "Debt" to the
Consolidated Financial Statements in Item 8. "Financial Statements and
Supplementary Data").

                                       65

  Table of Contents

On September 27, 2019, Adtalem closed on the sale of its Columbus, Ohio, campus
facility. Net proceeds of $6.4 million from the sale of this facility resulted
in a gain on the sale of $4.8 million in fiscal year 2020. This gain was
recorded at Adtalem's home office, which is classified as "Home Office and
Other" in Note 21 "Segment Information" to the Consolidated Financial Statements
in Item 8. "Financial Statements and Supplementary Data."

On April 24, 2020, Adtalem completed the sale of Adtalem Brazil to Estácio
Participações S.A. ("Estácio") and Sociedade de Ensino Superior Esta?io de Sá
Ltda, a wholly owned subsidiary of Estácio ("Purchaser"), pursuant to the Stock
Purchase Agreement dated October 18, 2019. Adtalem received $345.9 million in
sale proceeds and $56.0 million of Adtalem Brazil's cash, for a combined $401.9
million upon the sale. Adtalem Brazil's cash balance on the sale date was $88.4
million, resulting in $313.5 million of cash proceeds, net of this cash
transferred. In addition, Adtalem received $110.7 million from the settlement of
the deal-contingent foreign currency hedge arrangement to economically hedge the
Brazilian Real denominated purchase price through mitigation of the currency
exchange rate risk.

Financing Activities

The following table provides a summary of cash flows from financing activities
(in thousands):


                                                           Year Ended June 30,
                                                           2021           2020
Repurchases of common stock for treasury                $ (100,000)    $ 

(136,889)


Net proceeds from (repayments of) long-term debt            797,000      

(113,000)


Payment of debt issuance costs                             (18,047)        

-


Payment for purchase of redeemable noncontrolling
interest of subsidiary                                            -       

(6,247)


Other                                                       (2,487)        

3,493


Net cash provided by (used in) financing
activities-continuing operations                        $   676,466    $ 

(252,643)




On November 8, 2018, we announced that the Board authorized Adtalem's eleventh
share repurchase program, which allowed Adtalem to repurchase up to $300 million
of its common stock through December 31, 2021. The eleventh share repurchase
program commenced in January 2019 and was completed in January 2021. On February
4, 2020, we announced that the Board authorized Adtalem's twelfth share
repurchase program, which allows Adtalem to repurchase up to $300 million of its
common stock through December 31, 2021. The twelfth and current share repurchase
program commenced in January 2021. As of June 30, 2021, $245.2 million of
authorized share repurchases were remaining under the current share repurchase
program. Repurchases under our share repurchase programs were suspended on March
12, 2020 due to the economic uncertainty caused by the COVID-19 pandemic. In
November 2020, Adtalem resumed repurchases under its share repurchase programs.
Repurchases were again suspended in May 2021 after achieving management's target
of $100 million in repurchases for fiscal year 2021. The timing and amount of
any future repurchases will be determined based on an evaluation of market
conditions and other factors. See Note 15 "Share Repurchases" to the
Consolidated Financial Statements in Item 8. "Financial Statements and
Supplementary Data" for additional information on our share repurchase programs.

On March 24, 2020, we executed a pay-fixed, receive-variable interest rate swap
agreement (the "Swap") with a multinational financial institution to mitigate
risks associated with the variable interest rate on our Term B Loan debt. We pay
interest at a fixed rate of 0.946% and receive variable interest of one-month
LIBOR (subject to a minimum of 0.00%), on a notional amount equal to the amount
outstanding under the Term B Loan. The effective date of the Swap was March 31,
2020 and settlements with the counterparty occur on a monthly basis. The Swap
was set to terminate on February 28, 2025. During the operating term of the
Swap, the annual interest rate on the amount of the Term B Loan is fixed at
3.946% (including the impact of our current 3% interest rate margin on LIBOR
loans) for the applicable interest rate period. The Swap is designated as a cash
flow hedge and as such, changes in its fair value are recognized in accumulated
other comprehensive loss on the Consolidated Balance Sheet and are reclassified
into the Consolidated Statements of Income (Loss) within interest expense in the
periods in which the hedged transactions affect earnings. As of June 30, 2021,
the fair value of the Swap recorded within other liabilities was a loss of $8.9
million. On July 29, 2021, prior to refinancing our Credit Agreement (as
discussed below), we settled and terminated the Swap for $4.5 million, which
resulted in a charge to interest expense for this amount in the first quarter of
fiscal year 2022.

                                       66

  Table of Contents

As discussed in the previous section of this MD&A titled "Walden University
Acquisition," on August 12, 2021, Adtalem acquired all of the issued and
outstanding equity interest in Walden, in exchange for a purchase price of $1.48
billion in cash, subject to certain adjustments set forth in the Agreement. On
March 1, 2021, Adtalem Escrow Corporation (the "Escrow Issuer"), a wholly-owned
subsidiary of Adtalem, issued $800 million aggregate principal amount of 5.50%
Senior Secured Notes due 2028 (the "Notes"), which mature on March 1, 2028,
pursuant to an indenture, dated as of March 1, 2021 (the "Indenture"), by and
between the Escrow Issuer and U.S. Bank National Association, as trustee and
notes collateral agent. On February 12, 2021, Adtalem placed a $850 million
senior secured term loan ("New Term Loan") into the loan market. Funding under
the New Term Loan occurred at the same time as the closing of the Acquisition.
In addition, Adtalem secured a $400 million senior secured revolving loan
facility ("New Revolver") based on the commitment letter (the "Commitment
Letter") Adtalem entered into on September 11, 2020 with Morgan Stanley Senior
Funding, Inc. ("MSSF"), Barclays Bank PLC ("Barclays"), Credit Suisse AG, Cayman
Islands Branch ("CS") and Credit Suisse Loan Funding LLC ("CSLF" and, together
with CS and their respective affiliates, "Credit Suisse"), and MUFG Bank, Ltd.
(together with MSSF, Barclays and Credit Suisse, the "Commitment Parties"). We
refer to the New Revolver and New Term Loan collectively as the "New Credit
Facility." The New Credit Facility closed on August 12, 2021. The proceeds of
the Notes and the New Credit Facility were used, among other things, to finance
the Acquisition, refinance Adtalem's existing credit agreement, and pay fees and
expenses related to the Acquisition. The New Revolver will be used to finance
ongoing working capital and for general corporate purposes. As of June 30, 2021,
the amount of debt outstanding under the then effective credit facility was
$291.0 million. See Note 13 "Debt" to the Consolidated Financial Statements in
Item 8. "Financial Statements and Supplementary Data" for additional information
on our credit agreement and the financing agreements associated with the
Acquisition.

Management currently projects that COVID-19 will continue to have an effect on
operations and, as a result, liquidity, as discussed in the previous section of
this MD&A titled "Overview of the Impact of COVID-19"; however, we believe the
current balances of cash, cash generated from operations, and our New Credit
Facility (as defined and discussed in Note 13 "Debt" to the Consolidated
Financial Statements in Item 8. "Financial Statements and Supplementary Data")
will be sufficient to fund both Adtalem's current domestic and international
operations and growth plans for the foreseeable future.

Material Cash Requirements



Long-Term Debt - We have issued $800 million of Notes and maintain a $600
million credit facility, which requires principal and interest payments. As of
June 30, 2021, the amount of debt outstanding under our Credit Facility was
$291.0 million. See Note 13 "Debt" to the Consolidated Financial Statements in
Item 8. "Financial Statements and Supplementary Data" for additional information
on our credit agreement. As discussed in the previous section of this MD&A
titled "Liquidity and Capital Resources," on August 12, 2021, an $850 million
senior secured term loan was funded to provide funding for the Acquisition and
repay the then existing $291.0 million senior secured Term B loan. In addition,
on August 12, 2021, Adtalem secured a $400 million senior secured revolving loan
facility to replace the then existing $300 million revolving loan facility.

Operating Lease Obligations - We have operating lease obligations for the
minimum payments required under various lease agreements which are recorded on
the Consolidated Balance Sheet. In addition, we sublease certain space to third
parties, which partially offsets the lease obligations at these facilities. See
Note 11 "Leases" to the Consolidated Financial Statements in Item 8. "Financial
Statements and Supplementary Data" for additional information on our lease
agreements.

Contingencies

For a discussion of legal proceedings, see Note 20 "Commitments and Contingencies" to the Consolidated Financial Statements in Item 8 "Financial Statements and Supplementary Data."

Critical Accounting Estimates



We describe our significant accounting policies in the Notes to Consolidated
Financial Statements in Item 8. "Financial Statements and Supplementary Data."
The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities
as of the date of the financial statements, as well as the reported amounts

of
revenue

                                       67

  Table of Contents

and expenses during the reporting period. Critical accounting estimates
discussed below are those that we believe involve a significant level of
estimation uncertainty and have had or are reasonably likely to have a material
impact on our financial condition or results of operations. Management has
discussed our critical accounting estimates with the Audit and Finance Committee
of the Board. Although management believes its assumptions and estimates are
reasonable, actual results could differ from those estimates.

Although our current estimates contemplate current conditions, including the
impact of COVID-19, and how we anticipate them to change in the future, as
appropriate, it is reasonably possible that actual conditions could differ from
what was anticipated in those estimates, which could materially affect our
results of operations and financial condition. On March 11, 2020, the COVID-19
outbreak was declared a pandemic by the World Health Organization, which
recommended containment and mitigation measures worldwide. COVID-19 and the
response of governmental and public health organizations in dealing with the
pandemic included restricting general activity levels within communities, the
economy, and operations of our customers. While we have experienced an impact to
our business, operations, and financial results as a result of the COVID-19
pandemic, it may have even more far-reaching impacts on many aspects of our
operations including the impact on customer behaviors, business operations, our
employees, and the market in general. The extent to which the COVID-19 pandemic
ultimately impacts our business, financial condition, results of operations,
cash flows, and liquidity may differ from management's current estimates due to
inherent uncertainties regarding the duration and further spread of COVID-19,
actions taken to contain the virus, the efficacy and distribution of the
vaccines, as well as, how quickly and to what extent normal economic and
operating conditions can resume.

Credit Losses



The allowance for credit losses represents an estimate of the lifetime expected
credit losses inherent in our accounts receivable balances as of each balance
sheet date. In evaluating the collectability of all our accounts receivable
balances, we utilize historical events, current conditions, and reasonable and
supportable forecasts about the future. The estimate of our credit losses
involves a significant level of uncertainty as it requires significant judgment
to estimate the amount we will collect in the future on our account receivable
balances. See Note 9 "Accounts Receivable and Credit Losses" to the Consolidated
Financial Statements in Item 8. "Financial Statements and Supplementary Data"
for additional information on our credit losses.

Impairment of Long-Lived Assets


Long-lived assets are reviewed for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be
recoverable. If the carrying value is no longer recoverable based upon the
undiscounted future cash flows of the asset, the amount of the impairment is the
difference between the carrying amount and the fair value of the asset. Events
that may trigger an impairment analysis could include a decision by management
to exit a market or a line of business or to consolidate operating locations.
Future events could lead to future impairments of long-lived assets.

Goodwill and Intangible Assets

Goodwill and indefinite-lived intangibles are not amortized, but are tested for
impairment annually and when an event occurs or circumstances change such that
it is more likely than not that an impairment may exist. Our annual testing date
is May 31.

Adtalem first assesses goodwill for impairment qualitatively for each reporting
unit that contains goodwill. Management analyzes factors that include results of
operations and business conditions, significant changes in cash flows at the
reporting unit level, as well as how much previously calculated fair values
exceed carrying values to determine if it is more likely than not that the
reporting units have been impaired. If there is reason to believe the carrying
value of a reporting unit exceeds its fair value, then management performs a
quantitative impairment review. Adtalem uses a discounted cash flow model to
compute fair value. The estimated fair values of the reporting units are based
on management's projection of revenue, gross margin, operating costs, and cash
flows considering planned business and operational strategies over a long-term
planning horizon of five years. These reporting units constitute components for
which discrete financial information is available and regularly reviewed by
segment management and the Board. If the carrying amount of a

                                       68

Table of Contents



reporting unit containing the goodwill exceeds the fair value of that reporting
unit, an impairment loss is recognized to the extent of the excess, up to the
amount of goodwill recorded.

For indefinite-lived intangible assets, management first analyzes qualitative
factors, including results of operations and business conditions of each
reporting unit that contain indefinite-lived intangible assets, significant
changes in cash flows at the individual indefinite-lived intangible asset level,
if applicable, as well as how much previously calculated fair values exceed
carrying values to determine if it is more likely than not that the intangible
assets associated with these reporting units have been impaired. If there is
reason to believe the carrying value of an intangible asset exceeds its fair
value, then management performs a quantitative impairment review. In calculating
fair value, Adtalem uses various valuation techniques including a royalty rate
model for trade names and intellectual property and a discounted cash flow model
for Title IV eligibility and accreditation. The estimated fair values of these
indefinite-lived intangible assets are based on management's projection of
revenue, gross margin, operating costs, and cash flows considering planned
business and operational strategies over a long-term planning horizon of five
years. The assumed royalty rates and the growth rates used to project cash flows
and operating results are based upon historical results and analysis of the
economic environment in which the reporting units that record indefinite-lived
intangible assets operate. The valuations employ present value techniques to
measure fair value and consider market factors. Management believes the
assumptions used for the impairment testing are consistent with those that would
be utilized by a market participant in performing similar valuations of its
indefinite-lived intangible assets. If the carrying amount exceeds the fair
value, an impairment loss is recognized in an amount equal to that excess.

For intangible assets with finite lives, we evaluate for potential impairment
whenever events or changes in circumstances indicate that the carrying amount
may not be recoverable. If the carrying value is no longer recoverable based
upon the undiscounted future cash flows of the asset, the amount of the
impairment is the difference between the carrying amount and the fair value of
the asset. Intangible assets with finite lives are amortized over their expected
economic lives, ranging from 5 to 10 years.

All intangible assets and certain goodwill are being amortized for tax reporting purposes over statutory lives.



Determining the fair value of a reporting unit or an intangible asset involves
the use of significant estimates and assumptions. Management bases its fair
value estimates on assumptions it believes to be reasonable at the time, but
such assumptions are subject to inherent uncertainty. Actual results may differ
from those estimates, which could lead to future impairments of goodwill or
intangible assets. See Note 12 "Goodwill and Intangible Assets" to the
Consolidated Financial Statements in Item 8. "Financial Statements and
Supplementary Data" for additional information on our goodwill and intangible
assets impairment analysis.

Income Taxes

Adtalem accounts for income taxes using the asset and liability method. Under
this method, deferred tax assets and liabilities are recognized for the future
tax consequences of temporary differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax
bases. Adtalem also recognizes future tax benefits associated with tax loss and
credit carryforwards as deferred tax assets. Adtalem's deferred tax assets are
reduced by a valuation allowance, when in the opinion of management, it is more
likely than not that some portion or all of the deferred tax assets will not be
realized. Adtalem measures deferred tax assets and liabilities using enacted tax
rates in effect for the year in which Adtalem expects to recover or settle the
temporary differences. The effect of a change in tax rates on deferred taxes is
recognized in the period that the change is enacted. Adtalem reduces its net tax
assets for the estimated additional tax and interest that may result from tax
authorities disputing uncertain tax positions Adtalem has taken.

Contingencies



Adtalem is subject to contingencies, such as various claims and legal actions
that arise in the normal conduct of its business. We record an accrual for those
matters where management believes a loss is probable and can be reasonably
estimated. For those matters for which we have not recorded an accrual, their
possible impact on Adtalem's business, financial condition, or results of
operations, cannot be predicted at this time. A significant amount of judgment
and the use of estimates are required to quantify our ultimate exposure in these
matters. The valuation of liabilities for these contingencies is reviewed on a
quarterly basis to ensure that we have accrued the proper level of expense.

While we believe

                                       69

  Table of Contents

that the amount accrued to-date is adequate, future changes in circumstances
could impact these determinations. See Note 20 "Commitments and Contingencies"
to the Consolidated Financial Statements in Item 8. "Financial Statements and
Supplementary Data" for additional information on our loss contingencies.

Recent Accounting Pronouncements



For a discussion of recent accounting pronouncements, see Note 2 "Summary of
Significant Accounting Policies" to the Consolidated Financial Statements in
Item 8. "Financial Statements and Supplementary Data."

Non-GAAP Financial Measures and Reconciliations


We believe that certain non-GAAP financial measures provides investors with
useful supplemental information regarding the underlying business trends and
performance of Adtalem's ongoing operations and is useful for period-over-period
comparisons. We use these supplemental non-GAAP financial measures internally in
our assessment of performance and budgeting process. However, these non-GAAP
financial measures should not be considered as a substitute for, or superior to,
measures of financial performance prepared in accordance with GAAP. The
following are non-GAAP financial measures used in this Annual Report on Form
10-K:

Net income from continuing operations attributable to Adtalem excluding special
items (most comparable GAAP measure: net income (loss) attributable to
Adtalem) - Measure of Adtalem's net income (loss) attributable to Adtalem
adjusted for restructuring expense, business acquisition and integration
expense, pre-acquisition interest expense, gain on sale of assets, settlement
gains, gain on derivative, tax charges related to the implementation of the Tax
Act and the divestiture of DeVry University, a net tax benefit for a former
subsidiary investment loss, and loss from discontinued operations.

Earnings per share from continuing operations excluding special items (most
comparable GAAP measure: earnings (loss) per share) - Measure of Adtalem's
diluted earnings (loss) per share adjusted for restructuring expense, business
acquisition and integration expense, pre-acquisition interest expense, gain on
sale of assets, settlement gains, gain on derivative, tax charges related to the
implementation of the Tax Act and the divestiture of DeVry University, a net tax
benefit for a former subsidiary investment loss, and loss from discontinued
operations.

Operating income excluding special items (most comparable GAAP measure:
operating income) - Measure of Adtalem's operating income adjusted for
restructuring expense, business acquisition and integration expense, and gain on
sale of assets. This measure is applied on a consolidated and segment basis,
depending on the context of the discussion.

Effective income tax rate from continuing operations excluding special items
(most comparable GAAP measure: effective income tax rate from continuing
operations) - Measure of Adtalem's effective tax rate adjusted for tax effect on
gain on derivative and a net tax benefit for a former subsidiary investment
loss.

A description of special items in our non-GAAP financial measures described above are as follows:

Restructuring charges primarily related to real estate consolidations at

? Adtalem's home office and ACAMS, the write-down of EduPristine's assets, the

sale of Becker's courses for healthcare students, workforce reductions across

the organization, and the closing of the RUSM campus in Dominica.

? Business acquisition and integration expense include expenses related to the

Walden University acquisition.

? Pre-acquisition interest expense related to financing arrangements in

connection with the Walden University acquisition.

? Gain on the sale of Adtalem's Columbus, Ohio, campus facility.

Settlement gains related to the final insurance settlement related to

? Hurricanes Irma and Maria at AUC and RUSM and a lawsuit settlement against the

Adtalem Board of Directors.

Gain on the deal-contingent foreign currency hedge arrangement entered into in

? connection with the sale of Adtalem Brazil completed on April 24, 2020 to

economically hedge the Brazilian Real denominated purchase price through

mitigation of the currency exchange rate risk.

? Tax charges related to the implementation of the Tax Act and the divestiture of

DeVry University.

? A net tax benefit for a former subsidiary investment loss.




                                       70

  Table of Contents

? Loss from discontinued operations include the operations of Adtalem Brazil,

Carrington, and DeVry University.

The following tables provide a reconciliation from the most directly comparable GAAP measure to these non-GAAP financial measures. The operating income reconciliation is included in the results of operations section within this MD&A.



Net income (loss) attributable to Adtalem reconciliation to net income from
continuing operations attributable to Adtalem excluding special items (in
thousands):


                                                           Year Ended June 30,
                                                     2021          2020           2019
Net income (loss) attributable to Adtalem
(GAAP)                                            $   76,909    $  (85,334)    $   95,168
Restructuring expense                                  9,804         28,628

53,067


Business acquisition and integration expense          31,593              -             -
Pre-acquisition interest expense                      26,746              -

            -
Gain on sale of assets                                     -        (4,779)             -
Settlement gains                                           -              -      (26,178)
Gain on derivative                                         -      (110,723)             -
Tax Cuts and Jobs Act of 2017 and tax charges
related to the divestiture of DeVry University             -        (2,230)

3,584


Net tax benefit for a former subsidiary
investment loss                                            -       (25,688)             -

Income tax impact on non-GAAP adjustments (1) (16,501) (5,648)

(1,560)


Loss from discontinued operations                     25,127        329,315

12,079


Net income from continuing operations
attributable to Adtalem excluding special
items (non-GAAP)                                  $  153,678    $   123,541

$ 136,160

(1) Represents the income tax impact of non-GAAP continuing operations

adjustments that is recognized in our GAAP financial statements.

Earnings (loss) per share reconciliation to earnings per share from continuing operations excluding special items (shares in thousands):




                                                         Year Ended June 30,
                                                    2021         2020         2019

Earnings (loss) per share, diluted (GAAP)         $    1.49    $  (1.58)    $    1.60
Effect on diluted earnings per share:
Restructuring expense                                  0.19         0.53   

0.89


Business acquisition and integration expense           0.61            -   

-


Pre-acquisition interest expense                       0.52            -   

        -
Gain on sale of assets                                    -       (0.09)            -
Settlement gains                                          -            -       (0.44)
Gain on derivative                                        -       (2.05)            -
Tax Cuts and Jobs Act of 2017 and tax charges
related to the divestiture of DeVry University            -       (0.04)   

0.06


Net tax benefit for a former subsidiary
investment loss                                           -       (0.47)   

-

Income tax impact on non-GAAP adjustments (1) (0.32) (0.10)

(0.03)


Loss from discontinued operations                      0.49         6.09   

0.20


Earnings per share from continuing operations
excluding special items, diluted (non-GAAP)       $    2.98    $    2.28    $    2.29
Diluted shares used in EPS calculation               51,645       54,094   

59,330

(1) Represents the income tax impact of non-GAAP continuing operations


    adjustments that is recognized in our GAAP financial statements.


                                       71

  Table of Contents

Effective income tax rate from continuing operations reconciliation to effective
income tax rate from continuing operations excluding special items (in
thousands):


                                                                       Year Ended June 30,
                                                                  2021         2020          2019
Pre-tax results:

Income from continuing operations before income taxes (GAAP)   $  126,850   $   237,179   $  139,747
Gain on derivative                                                      -     (110,723)            -

Income from continuing operations before income taxes excluding special items (non-GAAP)

$  126,850

$ 126,456 $ 139,747

Taxes:


(Provision for) benefit from income taxes (GAAP)               $ (25,248)   $     6,358   $ (32,878)
Net tax benefit for a former subsidiary investment loss                 -      (25,688)            -
Provision for income taxes excluding special items
(non-GAAP)                                                     $ (25,248)

$ (19,330) $ (32,878)



Tax rate:
Effective income tax rate (GAAP)                                     19.9 %       (2.7) %       23.5 %
Effective income tax rate excluding special items (non-GAAP)         19.9 %

15.3 % 23.5 %


The calculation of the effective income tax rate from continuing operations
excluding special items in this MD&A does not include all of the same special
items used in our calculation of net income from continuing operations excluding
special items because we do not include all the special item adjustments from
our GAAP results in discussing our effective tax rates in this MD&A discussion.

© Edgar Online, source Glimpses